Cord Blood, Leukemia, Stem Cell Transplant
Conditions
Brief summary
To determine if the novel regimen of PT/FLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort
Detailed description
PTCy is a well-established haploidentical transplant regimen strategy. Moreover, unrelated cord blood (UCB) plays a critical role in the effects of GVL. However, the engraftment of grafts is unpredictable in the setting of a haplo-cord subsequent transplant. Therefore, applying a novel post-transplant regimen of PT/CY+FLU may selectively promote UCB engraftment in the setting of haplo-cord transplant.
Interventions
PROCEDUREapplying of FLU+CY post-HSCT
The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* children acute leukemia
Exclusion criteria
* MODS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rate of UCB engraftment | initiate STR detection from day+15 thereafter weekly up to 1 year post-HSCT | evaluate the regimen if it promotes UCB engraftment |
| rate of leukemia free survival | 3 years post-HSCT | determine the leukemia status post-HSCT |
| rate of overall survival | 3 years post-HSCT | determine the overall survival status post-HSCT |
Countries
China
Contacts
Primary ContactYongsheng Ruan, MD
Backup ContactXiaoqin Feng, MD
Outcome results
None listed